PharmaShots Weekly Snapshot (July 15– 19, 2019)


Gilead Signs an Exclusive Worldwide License Agreement with Novartis for its Three Preclinical Antiviral Programs

1.Gilead Signs an Exclusive Worldwide License Agreement with Novartis for its Three Preclinical Antiviral Programs

Published: Jul 19, 2019 | Tags: Gilead, Signs, Exclusive, Worldwide, License, Agreement, Novartis, Three, Preclinical, Antiviral, Programs

Amgen and Allergan Report Availability of Mvasi (biosimilar bevacizumab) and Kanjinti (biosimilar trastuzumab) in the US

2. Amgen and Allergan Report Availability of Mvasi (biosimilar bevacizumab) and Kanjinti (biosimilar trastuzumab) in the US

Published: Jul 18, 2019 | Tags:  Amgen, Allergan, Report, Availability, Mvasi, biosimilar, bevacizumab, Kanjinti, trastuzumab, the US

Mallinckrodt Signs an Agreement with Silence Therapeutics to Develop and Commercialize RNAi Therapeutics for Complement-Mediated Diseases

3. Mallinckrodt Signs an Agreement with Silence Therapeutics to Develop and Commercialize RNAi Therapeutics for Complement-Mediated Diseases

Published: Jul 18, 2019 | Tags: Mallinckrodt, Signs, Agreement, Silence Therapeutics, Develop, Commercialize, RNAi, Therapeutics, Complement-Mediated Diseases

Boehringer Ingelheim Reports Results of Ofev (nintedanib) in INMARK Study for Patients with Idiopathic Pulmonary Fibrosis (IPF)

4.Boehringer Ingelheim Reports Results of Ofev (nintedanib) in INMARK Study for Patients with Idiopathic Pulmonary Fibrosis (IPF)

Published: Jul 18, 2019 | Tags: Boehringer Ingelheim, Reports, Results, Ofev, nintedanib, INMARK Study, Patients, Idiopathic Pulmonary Fibrosis, IPF

Boehringer Ingelheim Signs a Worldwide License Agreement with Bridge Biotherapeutics for its BBT-877 — Draft Edit | | Trash | Preview

5. Boehringer Ingelheim Signs a Worldwide License Agreement with Bridge Biotherapeutics for its BBT-877 for $1.28B

Published: Jul 18, 2019 | Tags: Boehringer Ingelheim, Signs, Worldwide, License, Agreement, Bridge Biotherapeutics, Autotaxin, Inhibitor BBT-877

Interpace Diagnostics Signs an AI-Driven Agreement with Predictive Oncology for Diagnosing Thyroid Cancer

6. Interpace Diagnostics Signs an AI-Driven Agreement with Predictive Oncology for Diagnosing Thyroid Cancer

Published: Jul 18, 2019 | Tags: Interpace Diagnostics, Signs, AI-Driven, Agreement, Predictive Oncology, Diagnosing, Thyroid Cancer

Takeda and Chembio Diagnostics Collaborate to Develop Point-of-Care Diagnostic Test

7. Takeda and Chembio Diagnostics Collaborate to Develop Point-of-Care Diagnostic Test

Published: Jul 18, 2019 | Tags:Takeda, Chembio Diagnostics, Collaborate, Develop, Point-of-Care, Diagnostic Test

Astellas Signs a License Agreement with Frequency Therapeutics to Develop and Commercialize FX-322 for Hearing Loss

8.Astellas Signs a License Agreement with Frequency Therapeutics to Develop and Commercialize FX-322 for Hearing Loss

Published: Jul 17, 2019 | Tags: Astellas, Signs, License, Agreement, Frequency Therapeutics, Develop, Commercialize, FX-322, Hearing Loss

Bayer Signs a Clinical Collaboration Agreement with BMS and Ono to Evaluate Dual Regimen for Metastatic Colorectal Cancer

9. Bayer Signs a Clinical Collaboration Agreement with BMS and Ono to Evaluate Dual Regimen for Metastatic Colorectal Cancer

Published: Jul 18, 2019 | Tags: Bayer, BMS, Ono, Sign, Clinical Agreement, Evaluate, Dual Regimen, Metastatic Colorectal Cancer

Paragon Biosciences Launches a Facility for the Advancement of QuantX Medical Imaging AI System Diagnosing Breast Cancer

10.Paragon Biosciences Launches a Facility for the Advancement of QuantX Medical Imaging AI System Diagnosing Breast Cancer

Published: Jul 17, 2019 | Tags: Paragon Biosciences, Launches, Qlarity Imaging, Advance, QuantX, Medical Imaging, AI system, Diagnose, Breast Cancer

Novartis’ Kisqali (ribociclib) + Fulvestrant Receive NICE Approval for Advanced or Metastatic Breast Cancer

11.Novartis’ Kisqali (ribociclib) + Fulvestrant Receive NICE Approval for Advanced or Metastatic Breast Cancer

Published: Jul 17, 2019 | Tags: Novartis, Kisqali, ribociclib, Fulvestrant, Receive, NICE, Approval, Advanced, Metastatic, Breast Cancer   

MacroGenics Plans to Advance the Development of Flotetuzumab for Acute Myeloid Leukemia

12. MacroGenics Plans to Advance the Development of Flotetuzumab for Acute Myeloid Leukemia

Published: Jul 17, 2019 | Tags: MacroGenics, Plans, Advance, Development, Flotetuzumab, Acute Myeloid Leukemia

Genentech Signs a Research and License Agreement with Sosei Heptares to Develop GPCR Modulating Therapies

13. Genentech Signs a Research and License Agreement with Sosei Heptares to Develop GPCR Modulating Therapies

Published: Jul 16, 2019 | Tags:  Genentech, Signs, Research, License, Agreement, Sosei Heptares, Develop, GPCR, Modulating Therapies

Allergan Reports FDA’s Acceptance of NDA for Bimatoprost Sustained-Release to Treat Glaucoma or Ocular Hypertension

14. Allergan Reports FDA’s Acceptance of NDA for Bimatoprost Sustained-Release to Treat Glaucoma or Ocular Hypertension

Published: Jul 17, 2019 | Tags: Allergan, Reports, FDA, Acceptance, NDA, Bimatoprost, Sustained Release, Treat, Glaucoma, Ocular Hypertension

Merck’s Recarbrio (imipenem/cilastatin/relebactam) Receives the US FDA’s Approval for Complicated Urinary Tract and Complicated Intra-Abdominal Bacterial Infections

15. Merck’s Recarbrio (imipenem/cilastatin/relebactam) Receives the US FDA’s Approval for Complicated Urinary Tract and Complicated Intra-Abdominal Bacterial Infections

Published: Jul 17, 2019 | Tags: Merck, Recarbrio, imipenem, cilastatin, relebactam, Receives, US FDA, Approval, Complicated Urinary Tract, Complicated Intra-Abdominal Bacterial Infections

https://www.pharmashots.com/press-releases/puma-biotechnologys-licensing-partner-knight-therapeutics-receives-regulatory-approval-from-health-canada-to-commercialize-nerlynx-neratinib-for-extended-adjuvant-treatment-of-hormone-recep/

16. Knight Therapeutics’ Nerlynx (neratinib) Receives Health Canada Approval as Extended Adjuvant Therapy for HR+ and HER2+ Breast Cancer

Published: Jul 16, 2019 | Tags: Knight Therapeutics, Nerlynx, neratinib, Receives, Health Canada, Approval, Extended Adjuvant Therapy, HR, HER2, Positive, Breast Cancer

Genentech, Enters, Exclusive, Worldwide, Collaboration, Option, Acquire, Agreement, Convelo, Discover, Remyelinating Therapies

17.Genentech Enters into an Exclusive Worldwide Collaboration and Option to Acquire Agreement with Convelo to Discover Remyelinating Therapies

Published: Jul 16, 2019 | Tags: Genentech, Enters, Exclusive, Worldwide, Collaboration, Option, Acquire, Agreement, Convelo, Discover, Remyelinating Therapies

Genentech Signs an Exclusive Option and License Agreement with Skyhawk to Discover and Develop RNA Splicing Modifiers for Oncology and Neurodegenerative Diseases

18. Genentech Signs an Exclusive Option and License Agreement with Skyhawk to Discover and Develop RNA Splicing Modifiers for Oncology and Neurodegenerative Diseases

Published: Jul 16, 2019 | Tags: Genentech, Signs, Exclusive, Option, License, Agreement, Skyhawk, Discover, Develop, RNA, Splicing, Modifiers, Oncology, Neurodegenerative, Diseases

Novartis Reports FDA’s Acceptance of BLA for Crizanlizumab (SEG101)

19. Novartis Reports FDA’s Acceptance of BLA for Crizanlizumab (SEG101) to Treat Sickle Cell Disease

Published: Jul 16, 2019 | Tags: Novartis, Reports, FDA, Acceptance, BLA, Crizanlizumab, SEG101, Sickle Cell Disease

T-CiRA Research Collaboration Initiates Clinical Study of iCART Therapies for the Treatment of Cancer

20. T-CiRA Research Collaboration Initiates Clinical Study of iCART Therapies for the Treatment of Cancer

Published: Jul 16, 2019 | Tags: T-CiRA, Research. Collaboration, Initiates, Clinical Study, iCART, Therapies, Treatment, Cancer

Bayer's Gadavist (gadobutrol) Injection Receives the US FDA’s Approval for use in CMRI in Patients with Coronary Artery Disease

21. Bayer’s Gadavist (gadobutrol) Injection Receives the US FDA’s Approval for use in CMRI in Patients with Coronary Artery Disease

Published: Jul 15, 2019 | Tags: Bayer, Gadavist, gadobutrol, Injection, Receives, US, FDA, Approval, CMRI, Coronary Artery Disease

Abbott’s MitraClip G4 Receives the US FDA’s Approval for the Treatment of Mitral Regurgitation

22. Abbott’s MitraClip G4 Receives the US FDA’s Approval for the Treatment of Mitral Regurgitation

Published: June 15, 2019 | Tags: Abbott, MitraClip G4, Receives, US, FDA, Approval, Treatment, Mitral Regurgitation

Boehringer Ingelheim Acquires AMAL Therapeutics for its KISIMA Immunization Platform

23. Boehringer Ingelheim Acquires AMAL Therapeutics for its KISIMA Immunization Platform

Published: Jul 15, 2019 | Tags: Boehringer Ingelheim, Acquires, AMAL Therapeutics, KISIMA, Immunization Platform

AbbVie Acquires Mavupharma for its STING (STimulator of INterferon Genes) Modulators to Treat Cancer

24. AbbVie Acquires Mavupharma for its STING (STimulator of INterferon Genes) Modulators to Treat Cancer

Published: Jul 15, 2019 | Tags: AbbVie, Acquires, Mavupharma, STING, STimulator of INterferon Genes, Modulators, Treat Cancer

Janssen Reports Submission of BLA to the US FDA for Darzalex (daratumumab) Subcutaneous Formulation for Multiple Myeloma

25. Janssen Reports Submission of BLA to the US FDA for Darzalex (daratumumab) Subcutaneous Formulation for Multiple Myeloma

Published: Jul 12, 2019 | Tags: Janssen, Reports, Submission, BLA, US FDA, Darzalex, daratumumab, Subcutaneous Formulation, Multiple Myeloma

Gilead to Raise Stake in Galapagos with ~$5.1B Deal

26. Gilead to Raise Stake in Galapagos with ~$5.1B Deal

Published: Jul 14, 2019 | Tags: Gilead, Raise, Stake, Galapagos, $5.1B Deal

GSK Reports Results of Zejula (niraparib) in P-III PRIMA Study as 1L Maintenance Therapy for Ovarian Cancer

27. GSK Reports Results of Zejula (niraparib) in P-III PRIMA Study as 1L Maintenance Therapy for Ovarian Cancer

Published: Jul 15, 2019 | Tags: GSK, Reports, Results, Zejula, niraparib, P-III, PRIMA, Study, 1L, Maintenance, Therapy, Ovarian, Cancer